Frequently Asked Questions About RSV Immunization with Monoclonal Antibody for Children 19 Months and Younger

On October 23, 2023, CDC released a health advisory notice to communicate interim recommendations regarding the limited supply of nirsevimab, the new preventive antibody to protect infants against severe RSV.

Read more: Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations

Nirsevimab Indication, Dosage and Schedule

Timing of Nirsevimab Administration

Nirsevimab and RSV infection

Nirsevimab and Routine Childhood vaccines

Special Populations and Situations

Adverse Events After Nirsevimab Administration